Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …

Breast cancer is the second leading cause of cancer deaths among women. The
development of breast cancer is a multi-step process involving multiple cell types, and its …

Metastasis is the main cause of death for patients with breast cancer. Many studies have
characterized the genomic landscape of breast cancer during its early stages. However …

Immunotherapy using either checkpoint blockade or the adoptive transfer of antitumor
lymphocytes has shown effectiveness in treating cancers with high levels of somatic …

CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen
receptor–positive breast cancer. Mechanisms of CDK4/6 inhibitor resistance have been …

Triple-negative breast cancer (TNBC) is a highly heterogeneous disease, and molecular
subtyping may result in improved diagnostic precision and targeted therapies. Our previous …

Abstract Purpose The therascreen PIK3CA mutation assay and the alpha-specific PI3K
inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced …

Background High tumor mutation burden (TMB) can benefit immunotherapy for multiple
tumor types, but the prevalence of hypermutated breast cancer is not well described. The …

The whole-genome sequencing of prospectively collected tissue biopsies from 442 patients
with metastatic breast cancer reveals that, compared to primary breast cancer, tumor …

Background α-Selective phosphatidylinositol 3-kinase (PI3K) inhibitors improve outcome in
patients with PIK3CA-mutated, hormone receptor-positive (HR+)/Her2− metastatic breast …